Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK

Advances in Therapy

Volumn 35, Issue 5, 2018, Pages 724-736

  Strongman, Helen ^a   Kausar, Imran ^b   Maher, Toby M ^c,d  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b InterMune UK and Ireland   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

CPRD GOLD; Idiopathic pulmonary fibrosis; Incidence; Population based study; Prevalence; Respiratory; Survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE BURDEN; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; POPULATION RESEARCH; PREVALENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; UNITED KINGDOM; VERY ELDERLY; COHORT ANALYSIS; FACTUAL DATABASE; MORTALITY; NEWBORN; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TRENDS;

ADOLESCENT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; INFANT, NEWBORN; MALE; MORTALITY; PREVALENCE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; UNITED KINGDOM;

EID: 85047409733     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-018-0693-1     Document Type: Article

References (28)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–61.
2. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case–control study. Am J Epidemiol. 2000;152(4):307–15.
3. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest. 1998;113(2):396–400.
4. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–5.
5. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66(6):462–7.
6. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–72.
7. Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax. 1998;53(6):469–76.
8. Thickett DR, Kendall C, Spencer LG, et al. Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: a round table discussion. Thorax. 2014;69(12):1136–40.
9. National Institute of Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis. April 2013; NICE technology appraisal guidance 282.
10. National Institute of Health and Care Excellence. Nintedanib for treating idiopathic pulmonary fibrosis. 2016; NICE technology appraisal guidance 379.
11. National Institute of Health and Care Excellence. The diagnosis and management of suspected idiopathic pulmonary fibrosis. 2013.
12. Raghu G, Chen S-Y, Hou Q, Yeh W-S, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016;48(1):179–86.
13. Johnston I, Britton J, Kinnear W, Logan R. Rising mortality from cryptogenic fibrosing alveolitis. BMJ. 1990;301(6759):1017–21.
14. Hubbard R, Johnston I, Coultas DB, Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax. 1996;51(7):711–6.
15. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest. 2013;143(4):1078–84.
16. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.
17. Clinical Practice Research Datalink. 2014. http://www.cprd.com. Accessed Feb 2018.
18. Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read Codes, classifications and groupings. Proc AMIA Annu Fall Symp. 1996:75–9.
19. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.
20. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14.
21. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax. 1999;54(5):413–9.
22. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.
23. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
24. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5–8.
25. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
26. Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3-b Suppl):S17–S24.
27. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.
28. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.